Silver Book Fact

An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by $40 billion in 2020–from the projected $241 billion to $201 billion.

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.